Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact
 

June 18, 2009
Advances in Oncology Drug Development: Linking Drug Response Phenotypes to Multiplex Molecular Signatures 

Speakers for this event:
  • Jeffrey Settleman, Ph.D., Laurel Schwartz Professor of Oncology, Scientific Director, Massachusetts General Hospital Cancer Center  Learn More
  • Christine O’Day, Ph.D., Technical Director, In Vitro Pharmacology, MDS Pharma Services  Learn More
  • Dan Rhodes, Ph.D., CEO, Compendia Bioscience  Learn More

Advances in Oncology Drug Development: Linking Drug Response Phenotypes to Multiplex Molecular Signatures

The role genetics plays in the treatment of disease, and cancer in particular, has become increasingly apparent. Personalized medicine is expected to transform drug development from a ‘one-size-fits-all’ approach to one targeted to specific populations with genetic similarities. Join us to learn about how drug development strategies are changing to keep pace with these discoveries.

 

Hear from Jeffrey Settleman, PhD, distinguished professor of Oncology and researcher focused on targeted cancer therapies. Learn about the rational approach to using cellular pathways and oncogene addiction data of individual tumors for developing targeted therapies, smart drugs with less toxicity and more clinical success than general cytotoxic drugs.

 

Christine O’Day, PhD, will discuss the cell biology involved in screening compounds for understanding genetic sensitivity. Learn about the need for systematic cell culture control, sophisticated data capture and analysis, as well as the optimal selection of cell lines and genetic distribution of relevant panels.

 

Dan Rhodes, PhD, Founder and CEO of Compendia Bioscience and originator of Oncomine™ will explore biomarker discovery methodologies that integrate gene mutations, gene expression and DNA copy number. In addition, strategies to map in vitro biomarkers to clinical tumor populations will be discussed.

 

This webinar is part of a series sponsored by MDS Pharma Services

Webinar 4 (current page)
June 18/09
Advances in Oncology Drug Development: Linking Drug Response Phenotypes to Multiplex Molecular Signatures
For more information about Webinar 1 (On Demand Archive available)
October 23/08
First-In-Human Studies: Science-Driven Strategies
For more information about Webinar 2 (On Demand Archive available)
November 5/08
Leveraging a Multiphase QT Strategy to Expedite Development and Reduce Investment Risk: Cost Effective Design, Execution and Analysis
For more information about Webinar 3 (On Demand Archive available)
April 23/09
Quality On Time™ results with
APOLLO:RDA™ (Remote Data Access)
For more information about Webinar 5 (On Demand Archive available)
June 23/09
Insight and Innovation: Novel Approaches to Safety Pharmacology and Toxicology in the 21st Century
THIS PROGRAM IS INTENDED FOR:

Employees of large Pharma or Biotech companies who are:

  • Working with small molecules or biopharmaceuticals (biologics)
  • Active in the oncology field (whole pipeline)

Contact roles or positions include:

  • Medicinal Chemist
  • Discovery Biologist
  • Pharmacologist
  • Bioinformatics analyst
  • Safety Pharmacologist
  • Toxicologist
  • In Vivo Program Director
  • Product Manager
  • Sales & Marketing Manager
  • Clinical Researchers
  • Pharmacoepidemiologist
  • Translational Medicine

ABOUT OUR SPEAKERS:

 

Jeffrey Settleman, Ph.D., Laurel Schwartz Professor of Oncology, Scientific Director, Massachusetts General Hospital Cancer Center  

Dr. Settleman is an international leader in the study of cellular signaling pathways in human cancer. His current research is largely focused on molecularly targeted cancer therapeutics, personalized cancer medicine, and mechanisms of drug resistance. He received the Ph.D. degree in Genetics from Yale University in 1989, and from 1989-1992 was a postdoctoral fellow at the Whitehead Institute for Biomedical Research at M.I.T. in Dr. Robert Weinberg’s laboratory. He joined the Harvard School of Medicine faculty in 1992, and is currently the Laurel Schwartz Professor of Oncology at Harvard Medical School. He is also the Director of the Center for Molecular Therapeutics and the Scientific Director of the Massachusetts General Hospital Cancer Center, and leads the Cancer Cell Biology program of the Dana Farber Harvard Cancer Center. Dr. Settleman was the recipient of a Faculty Research Award from the American Cancer Society, and he has received awards from various foundations including the Avon Foundation, the Bertucci Foundation, the Saltonstall Foundation, the V Foundation, the Samuel Waxman Cancer Research Foundation, the Lustgarten Foundation, and the Lungevity Foundation. Dr. Settleman has authored more than 135 scientific publications and serves on the editorial boards of Developmental Cell, Molecular Biology of the Cell, and Molecular and Cellular Biology.

 

Christine O’Day, Ph.D., Technical Director, In Vitro Pharmacology, MDS Pharma Services  

Dr. Christine O’Day  has over 15 years of experience in drug development for cancer and diabetes.  She served as biochemistry group leader at Ceptyr, Inc. studying phosphatases and as a Director of Research at Oridigm Corporation where she worked on metabolic cancer agents.  In her endeavors, Christine gained extensive knowledge in the oncology field, as well as in assay development and data analysis.  She has years of experience in hit to lead discovery to the final stages of an IND. She received a Ph.D in Chemistry and Biology at Washington University studying DNA photolesions leading to cancer.  She currently leads the Cellular Biology Group at MDS Pharma Services.

 

Dan Rhodes, Ph.D., CEO, Compendia Bioscience  

Dr. Rhodes has an 8-year track record in cancer genomics and informatics with more than 30 papers published in peer-reviewed journals. He received a Ph.D. in Bioinformatics from the University of Michigan, contributing to several important advances in the field, including the seminal discovery of recurrent gene fusions in prostate cancer. Dr. Rhodes led the original development of Oncomine™ and the Oncomine Concepts Map in addition to several novel bioinformatics methods, including Meta-analysis of Microarrays and Cancer Outlier Profile Analysis (COPA), which led to the identification of recurrent gene fusions/translocations in prostate cancer (Science 5734:644) as well as the identification of Spink1 as a potential diagnostic and drug target in fusion negative prostate cancers (Cancer Cell 13:519) , and has since been added as a standard analysis feature in Oncomine.  He has received several awards for his work including the Harold Weintraub Award and the Team Science Award from the AACR. Dr. Rhodes also maintains a part-time faculty research position at the University of Michigan Center for Translational Pathology.

COMPANY PROFILES:

MDS Pharma Services, a business unit of MDS Inc., is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services.   For more information, visit our website at www.mdsps.com 

Compendia Bioscience is dedicated to harnessing the global collection of high-throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. For more information, go to www.compendiabio.com. 

 

ABOUT OUR MEDIA PARTNER:

Stay connected with your peers in our dynamic print and online community. Introducing, Cambridge Healthtech Media Group's suite of published resources focusing on the life sciences industry:

 

Bio-IT World Magazine- provides indispensable news, analysis, and opinion on the enabling technologies that are driving the drug discovery process.

Four topic specific eNewsletters (eCliniqua, Bio-IT World Weekly Update, PharmaWeek and Predictive Biomedicine) that provide timely, hard-hitting, and fact-based information on all aspects of the industry. Topics range from Predictive Biology, Clinical Trials, Drug Discovery, Development and much more!

We also offer custom integrated media packages that offer excellent exposure.

Visit us today at www.bio-itworld.com.

www.PharmCast.com is the world leading website designed specifically for pharmaceutical, clinical and biotechnology professionals.  www.PharmCast.com brings up-to-date information on pharmaceutical patents, FDA, news, jobs and Buyer's Guide to our visitors.  It was created and is maintained by pharmaceutical and biotechnology professionals.  Visit www.PharmCast.com and discover for yourself why it is so popular among professionals."

For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

 
Copyright © 2016-2017 Honeycomb Worldwide Inc.